Nonetheless, it has been suggested that the replacement of non-selective immunosuppressants, including steroids, mycophenolate mofetil, cyclophosphamide, and methotrexate, with precisely acting rituximab (anti-CD20), vedolizumab (anti-α4β7 integrin), tocilizumab (anti-IL-6), or anti-IL-12/23 blockers might be a better option in the management of cancer patients. The gene discussed is IL6; the disease is cancer.